Abstract
Despite the most notorious medical disaster caused by thalidomide in medical history, huge numbers of papers have been published about this drug since its formulation in 1956. While most of the early studies specifically concerned teratogenicity, recently there has been a resurgence of interest in thalidomide because of its potential for treating a number of otherwise intractable diseases, such as leprosy, human immunodeficiency virus replication in acquired immune deficiency syndrome, and cancer. Although the pharmacological aspects of the drug have been frequently reviewed, reviews focusing on thalidomide synthesis are rare. Here, the synthesis of thalidomide is reviewed in chronological order from the first report. We first aim to give an overview of the most conventional aspects of thalidomide. Subsequently, we will focus on the synthesis of racemic thalidomide, which is now commercially available. Finally, we will describe the asymmetric synthesis of thalidomide. To our knowledge, all the papers and patents concerning thalidomide synthesis have been introduced. Because of the number of papers and patents, we will not mention the preparation of thalidomide derivatives.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Harousseau J-L (2006) Future Oncol 2:577
Lepper ER, Smith NF, Cox MC, Scripture CD, Figg WD (2006) Curr Drug Metab 7:677
Teo SK, Stirling DI, Zeldis JB (2005) Drug Discov Today 10:107
Frank ME, Macpherson GR, Figg WD (2004) Lancet 363:1802
Laffitte E, Revuz J (2004) Expert Opin Drug Saf 3:47
Botting J (2002) Drug News Perspect 15:604
Ng SSW, Brown M, Figg WD (2002) Biomed Pharmacother 56:194
Razza A (2002) Biochemist 24:21
Hashimoto Y (2002) Bioorg Med Chem 10:461
Stirling D (2001) Semin Oncol 28:602
Jacobson JM (2000) Expert Opin Pharmacother 1:849
Franks ME, Marcpherson GR, Figg WD (2004) Lancet 363:1802
Waldman AR (2000) Clin J Oncol Nurs 4:99
Stephens TD, Bunde CJ, Filmore BJ (2000) Biochem Pharmacol 59:1489
McBride WG (1961) Lancet 278:1358
Lenz W, Pfeiffer RA, Kosenow W, Hayman DJ (1962) Lancet 279:45
Sheskin J (1965) Clin Pharmacol Ther 6:303
Chemie Grunenthal (1957) GB Patent 768821
Ose S, Umemoto S (1960) JP Patent 35005071
Ose S, Yoshimura Y, Saeki T (1960) JP Patent 35005277
Muller GW (1997) US Patent 5698579
Muller GW (1997) US Patent 5605914
Muller GW, Konnecke WE, Smith AM, Khetani VD (1999) Org Process Res Dev 3:139
Reepmeyer JC, Cox DC (1987) FDA monograph: guidelines to thalidomide synthesis. US Food & Drug Administration, Washington, DC
Caddick S (1995) Tetrahedron 51:10403
Perreux L, Loupy A (2001) Tetrahedron 57:9199
Lidstrom P, Tierney J, Wathey B, Westman J (2001) Tetrahedron 57:9225
Larhed M, Moberg C, Hallberg A (2002) Acc Chem Res 35:717
Kuhnert N (2002) Angew Chem Int Ed 41:1863
Blackwell HE (2003) Org Biomol Chem 1:1251
Kappe CO (2004) Angew Chem Int Ed 43:6250
Xu Y, Guo Q-X (2004) Heterocycles 63:903
Kirschning A, Solodenko W, Mennecke K (2006) Chem Eur J 12:5972
Seijas-Vazquez JA, Vazquez-Tato MP, Gonzalez-Bande C, Pacios-Lopez B (2003) ES Patent 2190707
Seijas JA, Vazquez-Tato MP, Gonzalez-Bande C, Martinez MM, Pacios-Lopez B (2001) Synthesis 999
Hijji YM, Benjamin E (2001) 5th International electronic conference on synthetic organic chemistry, 1–30 September 2001, p 1084
Hijji YM, Benjamin E (2002) 6th International electronic conference on synthetic organic chemistry, 1–30 September 2002, p 1084
Hijji YM, Benjamin E (2003) 7th International electronic conference on synthetic organic chemistry, 1–30 November 2003, p 1084
Hijji YM, Benjamin E (2004) 8th International electronic conference on synthetic organic chemistry, 1–30 November 2004, p 1084
Kassel DB (2001) Chem Rev 101:255
Amold FH (2001) Nature 409:253
Lehn J-M, Eliseev AV (2001) Science 291:2331
Schweizer F (2002) Angew Chem Int Ed 41:230
Brase S, Gil C, Knepper K (2002) Bioorg Med Chem 10:2415
Boger DL (2003) Bioorg Med Chem 11:1607
Brase S (2004) Acc Chem Res 37:805
Dolle RE (2004) J Comb Chem 6:623
Reymond J-L (2004) Angew Chem Int Ed 43:5577
Nefzi A, Ostresh JM, Yu J, Houghten RA (2004) J Org Chem 69:3603
Schwalbe T, Autze V, Hohmann M, Stimer W (2004) Org Process Res Dev 8:440
Spring DR (2005) Chem Soc Rev 34:472
Brown ED, Wright GD (2005) Chem Rev 105:759
Blotny G (2006) Tetrahedron 62:9507
Greco G, Novelino E, Martin YC (1998) Des Bioact Mol 219
Vedani A, Dobler M (2000) Prog Drug Res 55:105
Akamatsu M (2002) Curr Top Med Chem 2:1381
Mekenyan O (2002) Curr Pharm Des 8:1605
Schmieder P, Mekenyan O, Bradbury S, Veith G (2003) Pure Appl Chem 75:2389
Bultinck P, Winter HD, Langenaeker W, Tollenare J (eds) (2004) Computational Medicinal Chemistry for Drug Discovery, 1st edn. Marcel Dekker, New York
Debnath AK (2005) Curr Pharm Des 11:3091
Locuson CW, Wahlstrom JL (2005) Drug Metab Dispos 33:873
Allen DD, Geldenhuys WJ (2006) Life Sci 78:1029
Berger RD (2006) Drug Discov Today 11:429
Xiao Z, Schaefer K, Firestine S, Li P-K (2002) J Comb Chem 4:149
Chang M-Y, Chang C-H, Chen S-T, Chang N-C (2002) J Chin Chem Soc (Taipei) 49:383
Chang M-Y, Lin K-G, Chen S-T, Chang N-C (2003) J Chin Chem Soc (Taipei) 50:795
Chang M-Y, Chen S-T, Chang N-C (2003) Syn Commun 33:1375
Greig NH, Holloway H, Brossi A, Zhu X, Giordano T, Yu Q-S, Figg WD (2005) WO Patent 2005028436
Gao L, Yuan X, Guo H, Liu X (2003) CN Patent 1405166
Zhang H (2005) CN Patent 1597680
Yuan X-H, Guo H-Q, Qiu X-P, Kang C-Q, Liu X-D, Gao L-X (2005) Gaodeng Xuexiao Huaxue Xuebao 26:1477
Alpegiani M, Mazzoni A, Vergani D, Cabri W (2005) EP Patent 1602654
Varala R, Adapa SR (2005) Org Proc Res Dev 9:853
Blaschke G, Kraft HP, Fickentscher K, Kohler F (1979) Arzneimittelforschung 29:1640
Winter W, Frankus E (1992) Lancet 339:365
Blaschke G, Knoche B (1994) J Chromatogr 2:183
Nishimura K, Hashimoto Y, Iwasaki S (1994) Chem Pharm Bull 42:1157
Wnendt S, Finkam M, Winter W, Ossing J, Rabbe G, Zwingenberger K (1996) Chirality 8:390
Sampaio EP, Sarno EN, Gallily R, Cohn ZA, Kaplan G (1991) J Exp Med 173:699
Meyring M, Mühlbacher J, Messer K, Kastner-Pustet N, Bringmann G, Mannschreck A, Blaschke G (2002) Anal Chem 74:3726
De Camp WH (1989) Chirality 1:2
Ed. Chirality (1990) Lancet 336:1100
Lien EJ (1995) J Drug Target 2:527
Wnendt S, Zwingenberger Z (1997) Nature 385:303
Casini G, Ferappi M (1964) Farmaco Ed Sci 19:563
Shealy YF, Opliger CE, Montgomery JA (1965) Chem Ind 1030
Shealy YF, Opliger CE, Montgomery JA (1968) J Pharm Sci 57:757
Blaschke G, Kraft HP, Fickentscher K, Kohler F (1979) Arzneimittelforschung 29:1640
Blaschke G, Kraft HP, Markgraf H (1980) Chem Ber 113:2318
Francotte E, Wolf RM (1992) J Chromatogr 595:63
Reepmeyer JC (1996) Chirality 8:11
Chankvetadz B, Schulte G, Blaschke G (1997) J Pharm Biomed Anal 15:1577
Meyring M, Chankvetadze B, Blaschke G (2000) J Chromatogr A 876:157
Meyring M, Muhlenbrock C, Blaschke G (2000) Electrophoresis 21:3270
Zhang Y, Watts W, Nogle L, McConnell O (2004) J Chromatogr A 1049:75
Murphy-Poulton SF, Boyle F, Gu XQ, Mather LE (2006) J Chromatogr B 831:48
Robin S, Zhu J, Galons H, Pham-Huy C, Claude JR, Tomas A, Viossat B (1995) Tetrahedron Asymmetry 6:1249
Flaih N, Pham-Huy C, Galons H (1999) Tetrahedron Lett 40:3697
Suzuki E, Shibata N (2001) Enantiomer 6:275
Iong J, Shibata N, Toru T (2005) JP Patent 2005336157
Author information
Authors and Affiliations
Corresponding authors
Editor information
Rights and permissions
Copyright information
© 2007 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Shibata, N., Yamamoto, T., Toru, T. (2007). Synthesis of Thalidomide. In: Eguchi, S. (eds) Bioactive Heterocycles II. Topics in Heterocyclic Chemistry, vol 8. Springer, Berlin, Heidelberg. https://doi.org/10.1007/7081_2007_057
Download citation
DOI: https://doi.org/10.1007/7081_2007_057
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-72591-6
Online ISBN: 978-3-540-72592-3
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)